Intuitive Surgical (ISRG) 2025 — Grade A: Zero Debt, Zero Red Flags, Da Vinci Monopoly

Grade: A — Strong Financial Health

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-03) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP (PCAOB ID 238) — Clean opinion

One-line verdict: Intuitive Surgical is the gold standard of earnings quality. Revenue of $10.1B grew 20%, net income of $2.9B grew 23%, and operating cash flow of $3.0B covers net income at a 1.06x ratio — nearly perfect cash conversion. Every one of the 15 completed checks passes. No fails. No watch items. The Beneish M-Score of -2.44 is below the -2.22 safe threshold, and the Altman Z-Score of 12.01 confirms zero solvency risk. With no debt, $5.9B in cash, negligible goodwill ($370M, 2% of equity), and a razor-and-blade model that generates $6.0B in recurring instruments and accessories revenue, this is a financial fortress built on a surgical monopoly. The only concern, found in the footnotes rather than the quantitative checks: tariff risk from U.S. import duties on products manufactured in Mexico and Germany.

The Surgical Robotics Platform

Intuitive Surgical designs and manufactures robotic-assisted surgical systems. From the 10-K: "These platforms include da Vinci surgical systems, which are designed to enable a wide range of surgical procedures across a broad patient population using a minimally invasive approach, and the Ion endoluminal system, which extends our commercial offerings beyond surgery into diagnostic procedures."

The fifth-generation da Vinci 5 is the flagship: "featuring force feedback technology and instruments that enable surgeons to sense and measure the force exerted on tissue during surgery... Da Vinci 5 has more than 10,000 times the computing power of da Vinci Xi."

Revenue breakdown from the filing:

The filing states: "Total revenue increased in 2025 compared to 2024, primarily driven by 19% higher instruments and accessories revenue, 26% higher systems revenue, and 20% higher service revenue." Instruments and accessories revenue growth was "primarily driven by approximately 18% higher da Vinci procedure volume, approximately 51% higher Ion procedure volume."

U.S. revenue was $6,815.8M (68%) and OUS was $3,248.9M (32%).

System placements in 2025 included "incremental demand for our next-generation da Vinci 5 surgical system, an increase in trade-ins of our fourth-generation da Vinci surgical systems, and continued demand for additional capacity by our customers as a result of procedure growth."

Profitability: Exceptional Margins

The filing explains the gross margin decline: "gross profit margin decreased in 2025 compared to 2024, primarily driven by new tariffs, incremental fixed overhead costs, including depreciation expense associated with expanded manufacturing capacity, and higher costs associated with our da Vinci 5 surgical system, partially offset by lower excess and obsolete inventory charges."

Per the filing: "Operating income increased by 25% to $2.95 billion for the year ended December 31, 2025, compared to $2.35 billion for the year ended December 31, 2024. Operating income included $803 million and $688 million of share-based compensation expense."

Cash Flow: Near-Perfect Conversion

This is textbook earnings quality. CFFO/NI has been between 1.01 and 1.06 for three consecutive years — meaning essentially every dollar of reported net income is backed by a dollar of cash. The cash flow statement shows: net income of $2,876M (including noncontrolling interest), adjusted for $677M in share-based compensation, $445M in depreciation and disposal losses, $38M in deferred commission amortization, partially offset by $135M in deferred income tax benefits.

The filing notes that changes in operating assets and liabilities included "an increase in accounts receivable of $302 million, primarily due to increased sales and the timing of billings," offset by "an increase in deferred revenue of $75 million" and "an increase in accounts payable of $58 million."

Free cash flow surged to $2.5B as CapEx dropped from $1.1B to $540M — likely reflecting the completion of major manufacturing capacity expansion projects.

Balance Sheet: Fortress

Intuitive Surgical carries zero debt. The $370M in goodwill represents just 2% of $17.8B equity — negligible. The balance sheet is $20.5B in assets funded almost entirely by equity, with minimal current liabilities ($2.0B) and other long-term liabilities.

The Altman Z-Score of 12.01 reflects: strong working capital (X1 = 0.38), substantial retained earnings (X2 = 0.34), high operating profitability (X3 = 0.14), and an extremely high equity/liabilities ratio (X4 = 7.08). This score places Intuitive deep in the safe zone.

The Razor-and-Blade Model

The financial genius of Intuitive's business model is visible in the revenue mix. Instruments and accessories ($6.0B, 60% of revenue) is the recurring revenue stream — surgeons must use new instruments for each procedure, creating an annuity-like cash flow attached to each installed system. Service revenue ($1.6B, 16%) adds another recurring layer.

Systems revenue ($2.5B, 24%) is the "razor" — the upfront placement that locks in decades of consumable purchases. The 10-K states customers "place orders to replenish their supplies of instruments and accessories on a regular basis. Orders received are typically shipped within one business day."

This model explains the exceptional cash flow characteristics: recurring revenue with predictable demand, minimal credit risk (hospitals and health systems), and operating leverage as the installed base grows.

The 18-Point Screening

Beneish M-Score Component Breakdown:

Every M-Score component is benign. The AQI of 0.700 is particularly strong — it means hard assets (current assets + PPE) grew as a proportion of total assets, the opposite of what you see in companies inflating earnings through soft assets. The TATA of -0.009 confirms near-perfect alignment between reported earnings and cash generation.

Key Risks from the 10-K

1. Tariff Risk — Mexico and Germany Manufacturing

The 10-K discloses significant exposure: "changes in tariffs, trade barriers, and regulatory requirements (including changes to tariffs imposed by the U.S. on imports from various countries, including Mexico, where we currently manufacture a significant majority of our instruments and accessories, Germany, where we currently manufacture a majority of our endoscopes)." The filing specifically attributes the 1.5pp gross margin decline partly to "new tariffs."

2. Gross Margin Pressure from da Vinci 5

The filing states margin pressure came from "higher costs associated with our da Vinci 5 surgical system." As a new product ramping production, unit costs are higher. This should improve with scale, but near-term margins may remain under pressure.

3. Regulatory Risk

The 10-K warns extensively about FDA and international regulatory requirements: "Our products must meet the requirements of a large and growing body of international regulations and standards that govern product safety, efficacy, advertising, labeling, safety reporting, design, manufacture, materials content and sourcing."

4. Competition

The filing warns that "customers may choose our competitors' products or services or may not accept robotic-assisted medical procedures, which could result in reduced revenue and loss of customers." Medtronic (Hugo), Johnson & Johnson (Ottava), and others are entering the surgical robotics market.

5. Seasonality

"We have historically experienced lower procedure volume in the first and third quarters and higher procedure volume in the second and fourth quarters. More than half of da Vinci procedures performed are for benign conditions."

Key Financial Trends (4-Year)

Summary

Grade: A. Zero red flags. Zero watch items. This is how an earnings report should look.

Intuitive Surgical passes every completed check. Revenue grew 20% to $10.1B. Net income grew 23% to $2.9B. Operating cash flow of $3.0B converts at 1.06x net income — meaning $1.06 of cash for every $1 of reported profit. Free cash flow surged to $2.5B. The balance sheet carries no debt, negligible goodwill, and $5.9B in cash and investments.

The Beneish M-Score of -2.44 is cleanly below the -2.22 threshold. The F-Score probability is 0.13%. The Altman Z-Score of 12.01 is extremely strong. The accruals ratio of -0.9% is near zero.

The only concerns come from the qualitative 10-K disclosures rather than quantitative signals: tariff risk from Mexican and German manufacturing, margin pressure from the new da Vinci 5 system, and the emerging competitive threat from Medtronic and J&J. These are real business risks but not earnings quality concerns.

Intuitive Surgical's razor-and-blade model — $6.0B in recurring instruments and accessories revenue growing 19% per year, attached to an expanding installed base — is one of the highest-quality recurring revenue streams in the medical device industry. The numbers are clean. The cash is real.

**Disclaimer**: This report is based on Intuitive Surgical's fiscal year 2025 10-K filed with the SEC on February 3, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade A means the company passed all checks with strong financial health.